Dose Dense Chemotherapy Regimen Improves Survival In Breast Cancer
Novartis Begins Study Of Femara And Zometa In Postmenopausal Early Breast Cancer
Arimidex Continues To Show Improvement Over Tamoxifen
Iressa May Benefit Some Breast Cancer, Studies Find
Gleevec Improves Survival Of CML In Accelerated Phase
Phase II Study Tests Chemo Plus Mylotarg For AML
“Proof Of Concept” Shown In Early Trial Of PKC-412
Xeloda-Eloxatin Study Updated; Phase III Trial Interim Analysis
Clinical Trials Approved By NCI During November Are Listed
Trending Stories
- An opportunity for Trump: Position U.S. cancer science to lead the world
- Former Maryland Governor Larry Hogan to receive Public Service Leadership Award from National Coalition for Cancer Survivorship
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear” - Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs
To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges - NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced
NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”
